Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Seagen Inc
(NQ:
SGEN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 13, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Seagen Inc
< Previous
1
2
...
11
12
13
14
15
16
17
18
Next >
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
April 13, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case
April 11, 2022
A jury in Marshall, Texas, awarded Seagen Inc (NASDAQ: SGEN)
Via
Benzinga
Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
April 08, 2022
From
Seagen Inc.
Via
Business Wire
Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting
April 08, 2022
From
Seagen Inc.
Via
Business Wire
What 7 Analyst Ratings Have To Say About Seagen
February 10, 2022
Seagen (NASDAQ:SGEN) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022
April 07, 2022
From
Seagen Inc.
Via
Business Wire
Good Entry Point for Biotech Stocks
April 04, 2022
Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms.
Via
Talk Markets
Top Nasdaq 100 Stocks: Trading Opportunities For Next Week
April 03, 2022
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some Nasdaq 100 stock opportunities by...
Via
Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
March 17, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets
March 16, 2022
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
March 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
March 16, 2022
From
Seagen Inc.
Via
Business Wire
Tough Slogging Ahead for Investors, Diversification is Important
March 07, 2022
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.
Via
Talk Markets
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
February 28, 2022
From
Seagen Inc.
Via
Business Wire
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
February 24, 2022
From
Seagen Inc.
Via
Business Wire
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
February 24, 2022
From
Genmab A/S
Via
Business Wire
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
February 17, 2022
Can the formerly red-hot biotech segment return to its previous glory?
Via
Investor's Business Daily
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
February 15, 2022
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (...
Via
Benzinga
Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
February 14, 2022
From
Seagen Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
February 11, 2022
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.6% to $1.35 during Friday's regular session. As of 12:30 EST, Dermata Therapeutics's stock is...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 11, 2022
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock rose 29.0% to $1.38 during Friday's pre-market session. The company's market cap stands at $11.4 million. Innoviva...
Via
Benzinga
Netflix And Sirius XM Lead The Nasdaq Sharply Lower
February 10, 2022
U.S. indices were trading lower Thursday following comments from St. Louis Fed President James Bullard indicating he favors a 1% rate increase by J...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
February 10, 2022
On Thursday, 89 companies hit new 52-week lows. Noteable 52-Week Lows: The company with the largest market cap to set a new 52-week low was Seagen (NASDAQ:SGEN)....
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
February 10, 2022
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.1% to $1.35 during Thursday's regular session. The current volume of 17.5 million shares is 7266....
Via
Benzinga
Seagen Crumbles With AstraZeneca Expected To Pressure Its New Drug
February 10, 2022
Seagen called for lower-than-expected 2022 sales of Tukysa, a breast cancer drug.
Via
Investor's Business Daily
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
10 Biggest Price Target Changes For Thursday
February 10, 2022
Macquarie boosted the price target on Twilio Inc. (NYSE: TWLO) from $281 to $306. Twilio shares jumped 20.4% to $243.23 in pre-market trading.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 10, 2022
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 27.1% to $1.36 during Thursday's pre-market session. The company's market cap stands at $11.3...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
February 10, 2022
Good morning, trader! Rub that sleep out our your eyes because we're going over the biggest pre-market stock movers for Thursday!
Via
InvestorPlace
Why Are Seagen Shares Sinking Today?
February 10, 2022
Seagen Inc (NASDAQ: SGEN) reported Q4 revenues
Via
Benzinga
< Previous
1
2
...
11
12
13
14
15
16
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.